

C3 506 D3 7.(amended) The isolated HLA class II-binding peptide of claim 2 wherein the isolated peptide is non-hydrolyzable.

507 D4 9.(amended) A composition comprising an isolated MAGE-A1 HLA class I-binding peptide and an isolated MAGE-A1 HLA class II-binding peptide, wherein the isolated HLA class II-binding peptide consists essentially of the amino acid sequence set forth as SEQ ID NO:7, or a functional variant thereof comprising one amino acid addition, substitution or deletion, and 0-10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, or the functional variant thereof.

C5 508 D6 76.(amended) The isolated HLA class II-binding peptide of claim 2 wherein the isolated peptide consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:7.

509 D11 C6 81.(amended) The composition of claim 9 wherein the isolated MAGE-A1 HLA class II-binding peptide consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:7.

510 D12 82.(amended) The composition of claim 9 wherein the isolated MAGE-A1 HLA class II-binding peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:7.

#### Remarks

Applicants have canceled claims 1 and II. Claims 2, 9, 76 and 81 have been amended to clarify the subject matter of the claims. Support for the amendments to these claims can be found in the claims as filed and in the specification at page 11, lines 31-32. Claims 5, 7, 81 and 82 have been amended to alter the claim dependencies in view of the claim cancellations. No new matter has been added.